Certara Services Archives

Case Study

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…

CertaraOctober 2, 2023

White Paper

ICER’s Unsupported Price Increase Report: Unfit for Policymaking

Since 2019, the Institute for Clinical and Economic Review (ICER) has published an annual Unsupported…

CertaraJuly 25, 2023

Case Study

Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program

Certara's support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make…

CertaraJune 1, 2023

Case Study

Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, developed RHB-204, a treatment for MAC, and needed…

CertaraMay 9, 2023

Case Study

Using MBMA to run virtual “head-to-head trials”

Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…

CertaraApril 21, 2023

Case Study

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…

CertaraApril 17, 2023

Case Study

Using Real World Evidence to Inform Treatment Guidelines

Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…

CertaraApril 5, 2023

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

CertaraApril 5, 2023

Case Study

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…

CertaraJune 1, 2022

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Certara Services

Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)

ICER’s Unsupported Price Increase Report: Unfit for Policymaking

Leveraging Pharmacokinetic Modeling & Scientific Communications Expertise Advances Sarcoidosis Drug Program

Translational Pharmacology Consulting Supports Combination Therapy for Treating Pulmonary Mycobacterium Avium Complex Disease

Using MBMA to run virtual “head-to-head trials”

Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial

Using Real World Evidence to Inform Treatment Guidelines

Using Real Word Evidence to Enhance Drug Development

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Newsletter sign up

Quick links

Solutions

Contact